Your browser doesn't support javascript.
loading
Evaluation of exacerbations and blood eosinophils in UK and US COPD populations.
Vogelmeier, Claus F; Kostikas, Konstantinos; Fang, Juanzhi; Tian, Hengfeng; Jones, Bethan; Morgan, Christopher Ll; Fogel, Robert; Gutzwiller, Florian S; Cao, Hui.
Afiliação
  • Vogelmeier CF; Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Centre Giessen and Marburg, Philipps-University Marburg, Member of the German Center for Lung Research (DZL), 35043, Marburg, Germany. vogelmei@med.uni-marburg.de.
  • Kostikas K; Respiratory Medicine Department, University of Ioannina School of Medicine, Ioannina, Greece.
  • Fang J; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Tian H; KMK Consulting Inc, Morristown, NJ, USA.
  • Jones B; Pharmatelligence, Cardiff, UK.
  • Morgan CL; Pharmatelligence, Cardiff, UK.
  • Fogel R; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Gutzwiller FS; Novartis Pharma AG, Basel, Switzerland.
  • Cao H; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Respir Res ; 20(1): 178, 2019 Aug 07.
Article em En | MEDLINE | ID: mdl-31391053
ABSTRACT

BACKGROUND:

Blood eosinophil counts and history of exacerbations have been proposed as predictors of patients with chronic obstructive pulmonary disease (COPD) who may benefit from triple therapy (inhaled corticosteroid, long-acting ß2-agonist and long-acting muscarinic antagonist).

METHODS:

In a retrospective cohort analysis we examined the profiles of COPD patients from the UK Clinical Practice Research Datalink (CPRD) and US Optum Clinformatics™ Data Mart (Optum) databases with reference to exacerbation frequency and blood eosinophil distribution.

RESULTS:

Of the 31,437 (CPRD) and 383,825 (Optum) patients with COPD, 15,364 (CPRD) and 139,465 (Optum) met the eligibility criteria and were included. Among patients with ≥2 exacerbations and available eosinophil counts in the baseline period (CPRD, n = 3089 and Optum, n = 13414), 17.0 and 13.3% respectively had eosinophil counts ≥400 cells/µL. Patients with ≥2 exacerbations or eosinophil count ≥400 cells/µL during first year, exacerbated at least once (CPRD, 82.8% vs Optum, 80.6%) or continued to have eosinophil count ≥300 cells/µL (76.8% vs 76.5%), respectively in the follow-up year. In both years, a higher variability in the number of exacerbations and eosinophil count was observed in patients with one exacerbation and eosinophil counts between 300 and 400 cells/µL; patients with eosinophil count < 150 cells/µL had the lowest variability. Approximately 10% patients had both ≥2 exacerbations and eosinophil count ≥300 cells/µL across the databases.

CONCLUSION:

A high variability in blood eosinophil counts over two consecutive years was observed in UK and US patients with COPD and should be considered while making treatment decisions. A small proportion of COPD patients had frequent exacerbations and eosinophil count ≥300 cells/µL.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vigilância da População / Doença Pulmonar Obstrutiva Crônica / Eosinófilos / Exacerbação dos Sintomas Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: America do norte / Europa Idioma: En Revista: Respir Res Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vigilância da População / Doença Pulmonar Obstrutiva Crônica / Eosinófilos / Exacerbação dos Sintomas Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: America do norte / Europa Idioma: En Revista: Respir Res Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Alemanha